Xella Health closes US$3.7 million in pre-seed financing

Xella Health has closed more than US$3.7m in pre-seed financing as it prepares to launch a women’s precision health platform in spring 2026.

The company, which says it is approaching a 10,000-person waitlist, combines multi-omic diagnostics, longitudinal data (tracked over time) and clinician-led guidance to help women understand their biology across fertility, hormonal health, chronic conditions, early cancer detection and preventative care.

Xella says it is pioneering the use of menstrual fluid alongside peripheral blood to access biological signals that have historically been ignored.

The company claims this approach can provide insights into the root causes of menstrual irregularities and chronic pelvic pain, scores for egg quality and quantity, miscarriage risk, specific perimenopause stage, HRT personalisation guidance, genetic predispositions for reproductive cancers and whole-body ageing insights.

Kelly Lacob, co-founder and chief executive of Xella, said: “Our mission is to give women the answers and care they have always deserved.

“Xella is building the infrastructure to decode female biology–getting to the root cause of conditions that uniquely, differently or disproportionately affect women, many of which suffer from an unacceptably poor standard of care today.

“Every woman who comes to Xella works with a dedicated clinician-coach, supported by AI, to ensure that the complex data we analyse translates into meaningful, actionable health outcomes rather than more noise. This funding allows us to accelerate product development and prepare for our first launch.”

The company was co-founded by Lacob alongside Adriana Dantas, chief operating officer, and Jesus Ching, chief technology officer.

The funding round was led by Precursor Ventures, with participation from Capital F, Ulu Ventures and other funds, as well as angel investors across healthcare, diagnostics and consumer technology.

Ashtan Jordan, principal at Precursor Ventures, said: “Xella is rethinking women’s health from the ground up—starting with the insight women need to make sense of their own biology over time.

“The team is building with a rare combination of scientific depth, product intuition, and empathy for the lived realities of women, which is exactly what’s required to create a trusted, enduring platform in healthcare.”

The capital will be used to finalise product development, expand partnerships and support the company’s market launch.